PA
INBX

Perceptive Advisors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Perceptive Advisors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,256,104
Closed -$149M – 133
2024
Q1 		$149M Hold
4,256,104
– – 2.6% 6
2023
Q4 		$162M Hold
4,256,104
– – 3.61% 6
2023
Q3 		$78.1M Buy
4,256,104
+631,922
+17% +$13.2M 2.61% 9
2023
Q2 		$94.1M Buy
3,624,182
+8,799
+0.2% +$205K 2.72% 8
2023
Q1 		$68.2M Buy
3,615,383
+301,600
+9% +$7.01M 2.01% 11
2022
Q4 		$81.7M Buy
3,313,783
+425,923
+15% +$12.5M 2.29% 12
2022
Q3 		$51.8M Buy
2,887,860
+973,268
+51% +$17.5M 1.5% 17
2022
Q2 		$21.7M Buy
1,914,592
+133,357
+7% +$1.96M 0.68% 38
2022
Q1 		$39.7M Buy
1,781,235
+437,745
+33% +$11.2M 0.79% 33
2021
Q4 		$58.7M Buy
1,343,490
+222,000
+20% +$8.88M 0.9% 29
2021
Q3 		$37.4M Buy
1,121,490
+214,400
+24% +$6.52M 0.54% 46
2021
Q2 		$25M Buy
+907,090
New +$18.9M 0.32% 76

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Perceptive Advisors's INBX Position: Q2 2024 in Review

Perceptive Advisors sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 4,256,104 shares — an estimated $149M sold.

Perceptive Advisors first reported a position in INBX in Q2 2021 and held it in 12 quarters. The position peaked at $162M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Perceptive Advisors reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Perceptive Advisors sold 4,256,104 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $149M.
  • Perceptive Advisors first reported a position in Inhibrx, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Perceptive Advisors's Inhibrx, Inc. Common Stock position peaked at $162M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.